US 20210255168A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0255168 A1**

ABU KHABAR (43) **Pub. Date: Aug. 19, 2021**

(54) **A METHOD OF PRECISION CANCER THERAPY**

(71) Applicant: **KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE**, RIYADH (SA)

(72) Inventor: **KHALID S. ABU KHABAR**, RIYADH (SA)

(21) Appl. No.: **16/973,573**

(22) PCT Filed: **Jun. 13, 2019**

(86) PCT No.: **PCT/EP2019/065585**

§ 371 (c)(1),
(2) Date: **Dec. 9, 2020**

Related U.S. Application Data

(63) Continuation-in-part of application No. 16/007,146, filed on Jun. 13, 2018.

Publication Classification

(51) **Int. Cl.**
G01N 33/50 (2006.01)

(52) **U.S. Cl.**
CPC ***G01N 33/5017*** (2013.01); *G01N 2500/04* (2013.01)

(57) **ABSTRACT**

The present invention relates to a method of treatment of cancer, said method comprising administering an effective dose of a protein kinase inhibitor to a patient in need thereof having said cancer. The present invention also relates to a method of post-transcriptional control of cancer-related genes comprising administering an effective amount of a protein kinase inhibitor to a subject in need thereof. The present invention further relates to a method of identifying a protein kinase inhibitor for normalizing post-transcriptional regulation as precision cancer therapy.

Specification includes a Sequence Listing.